Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 25, 2026 - P1 | N=22 | Active, not recruiting | Sponsor: Beth Christian | Trial completion date: Aug 2026 ➔ Apr 2027
Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BCL2
|